Status:
TERMINATED
Characterization of Treatment Responses in Lymphedema
Lead Sponsor:
Stanford University
Conditions:
Lymphedema
Eligibility:
All Genders
18-75 years
Brief Summary
This study is designed to investigate the treatment response of lymphedema, of the upper or lower extremity, during clinical, pharmacologic treatment of lymphedema with oral ketoprofen. Correlation of...
Detailed Description
Patients presenting to the Investigator's Clinic for evaluation and treatment of (upper or lower extremity) lymphedema, will be assessed for their suitability (of low risk) for medical treatment with ...
Eligibility Criteria
Inclusion
- Participants with a history of acquired lymphedema
- Stage 1, 2, or 3
- 18-75 years
- Clinical use of ketoprofen for lymphedema
Exclusion
- Active cancer, infection, bleeding tendency, inflammatory disease and/or taking anti-inflammatory or anti-leukotriene medication will be excluded.
- Pregnant or lactating females
- Inability to take ketoprofen (contra-indicated, e.g patients with known CV, GI, renal, hepatic disease).
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation, may interfere with interpretation of study results, and in the judgement of the investigator, would make the participation inappropriate for entry into this study.
Key Trial Info
Start Date :
June 21 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2023
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT03783715
Start Date
June 21 2019
End Date
August 31 2023
Last Update
October 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Stanford, California, United States, 94305